secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2021-12-16T23:59:59+00:00
Accession:  0001193125-21-358580
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NMPA approves Zai Lab's NUZYRA as Category 1 innovative drug for CABP and ABSSSI
--------------------------------------------------------------------------------

- NMPA approved NUZYRA (omadacycline) for community-acquired bacterial pneumonia and acute bacterial skin infections.
- Approved as Category 1 innovative drug; locally manufactured in China; Zai Lab's fourth product approval in 24 months.
- NUZYRA offers IV and oral formulations, targeting multi-drug-resistant bacteria; first Zai Lab product outside oncology.
- Approval based on three Phase 3 studies in Chinese patients; NUZYRA previously FDA-approved and marketed by Paratek in US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000119312521358580/0001193125-21-358580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000119312521358580/d26405d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-358580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer